Karyopharm Therapeutics Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
Für Karyopharm Therapeutics wird ein Gewinn- und Umsatzwachstum von 53.9% bzw. 30.5% pro Jahr prognostiziert, während der Gewinn je Aktie voraussichtlich um 68.9% pro Jahr steigen soll.
Wichtige Informationen
53.9%
Wachstumsrate der Gewinne
68.93%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 24.9% |
| Wachstumsrate der Einnahmen | 30.5% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 08 Jun 2026 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Narrativ-Update • Jun 07
KPTI: Phase 3 Myelofibrosis Data Will Drive 2026 Frontline Opportunity
Analysts have revised their price target on Karyopharm Therapeutics, citing updated views on fair value, growth, and profitability assumptions. The new target is $13.50, compared with the prior $15.33.
Narrativ-Update • May 03
KPTI: Selinexor Commercialization And Funding Pressures Will Likely Constrain Future Upside
Analyst price targets for Karyopharm Therapeutics have shifted, with recent cuts and a subsequent $8 increase tied to reassessments of revenue potential, profit margins and future P/E assumptions around selinexor and the broader pipeline. Analyst Commentary Recent Street research on Karyopharm Therapeutics shows a mixed picture, with one price target increase following several cuts over a relatively short window.Narrativ-Update • Apr 19
KPTI: Funding Uncertainty And Execution Risks Will Likely Cap Future Returns
Analysts have trimmed their average price target on Karyopharm Therapeutics by several dollars, citing updated views on discount rates, revenue assumptions and long term profit margins following recent Street research. Analyst Commentary Recent Street research shows several bearish analysts cutting their Karyopharm price targets by mid single digit to high single digit dollar amounts, pointing to revised assumptions on discount rates, revenue potential and long term margins.Narrativ-Update • Apr 04
KPTI: Funding Strains And Execution Risks Will Likely Restrain Future Upside
The Street’s blended fair value estimate for Karyopharm has been trimmed by $1.00 to $5.00, as analysts fold in lower projected revenue growth, a slightly softer profit margin outlook, a higher discount rate, and updated P/E assumptions following recent target cuts from multiple firms. Analyst Commentary Recent Street research has tilted more cautious on Karyopharm, with multiple bearish analysts cutting price targets and reassessing the risk profile around execution, profitability, and the timing and scale of future revenue contributions.Seeking Alpha • Mar 26
Karyopharm: Putting The Phase 3 Trial In Context
Summary Karyopharm Therapeutics faces heightened uncertainty after mixed phase 3 SENTRY results for selinexor in myelofibrosis. KPTI met the spleen volume reduction endpoint but missed symptom improvement while showing a promising, though immature, overall survival signal. A dire cash position persists despite a $30 million private placement; the runway extends only into Q2 2026, with existential funding risks looming. I maintain a tentative 'Buy' rating, citing deep pessimism and multiple 2026 catalysts, but caution against aggressive position sizing due to liquidity and funding risks. Read the full article on Seeking AlphaNarrativ-Update • Mar 21
KPTI: Phase 1 Myelofibrosis Data Will Support 2026 Frontline Opportunity
Analysts have adjusted their price target for Karyopharm Therapeutics to $28, citing confidence in selinexor's differentiated mechanism of action, compelling Phase 1 data in myelofibrosis, and a projected peak revenue opportunity of $800m to $850m in frontline myelofibrosis, with further potential from multiple myeloma programs. Analyst Commentary Bullish Takeaways Bullish analysts see selinexor's differentiated mechanism of action as a key driver for long term value, supporting the $28 price target as they factor in a distinct clinical profile within myelofibrosis.
Narrativ-Update • Mar 07
KPTI: Refreshed Revenue And Margin Outlook Will Support Bullish Repricing
Analysts have updated their price target on Karyopharm Therapeutics from $66.25 to $23.00, citing refreshed assumptions around revenue growth, profit margins, discount rate, and future P/E following recent bullish Street research. Analyst Commentary Bullish analysts are framing the reset in price target to $23.00 as part of a broader constructive view on Karyopharm Therapeutics, where refreshed modeling assumptions are more closely aligned with recent positive Street research.Narrativ-Update • Feb 20
KPTI: Execution And Funding Risks Will Likely Cap Bullish Repricing
Analysts have raised their $6.00 price target for Karyopharm Therapeutics, citing slightly lower perceived risk, a modestly stronger revenue outlook, and a small increase in the expected future P/E as the key factors behind the update. Analyst Commentary Recent research commentary around Karyopharm Therapeutics has centered on how much risk investors should assign to the story, how sustainable the current revenue trajectory may be, and what a reasonable P/E might look like given execution needs ahead.Narrativ-Update • Feb 06
KPTI: Lower Risk View Will Support 2026 Myelofibrosis Phase III Milestone
Analysts have modestly raised their price target on Karyopharm Therapeutics to US$15.33, citing a slightly lower required return and similar long term growth and margin assumptions that keep the fair value estimate steady. Analyst Commentary Recent Street research has focused on how the updated price target for Karyopharm Therapeutics lines up with its risk profile and execution needs, rather than materially changing long term growth or margin assumptions.Narrativ-Update • Jan 23
KPTI: Extended Cash Runway Will Support 2026 Myelofibrosis Phase III Milestone
Narrative update on Karyopharm Therapeutics Analysts have nudged their fair value estimate for Karyopharm Therapeutics higher from US$14.67 to US$15.33, citing recent Street research that points to steady Xpovio sales, reduced financing overhangs, maintained MF timelines into March 2026, and updated price targets that reflect the latest financing transactions. Analyst Commentary Recent Street research highlights a mix of optimism around execution and caution around financing and valuation as analysts update their views on Karyopharm Therapeutics.Analyseartikel • Jan 11
Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Prospects Need A Boost To Lift Shares
You may think that with a price-to-sales (or "P/S") ratio of 1.1x Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) is...Narrativ-Update • Jan 09
KPTI: Financing Overhangs Will Likely Outweigh MF Timeline Support
Analysts have trimmed their 12 month price target on Karyopharm Therapeutics to US$19 from US$30, citing recent financing transactions. They also point to solid Xpovio sales and maintained MF timelines into March 2026 as support for the stock’s overall risk and reward profile.Narrativ-Update • Dec 25
KPTI Extended Cash Runway Will Likely Be Outweighed By Dilution Risk
Analysts have cut their price target on Karyopharm Therapeutics to about $6 from roughly $8 per share, citing the impact of recent financing transactions on valuation. At the same time, extended cash runway, solid Xpovio sales and visibility into key 2026 myelofibrosis data support a still constructive risk and reward profile.Narrativ-Update • Dec 11
KPTI: Extended Cash Runway Will Support Pivotal 2026 Myelofibrosis Phase III Readout
Analysts have modestly reduced their price targets on Karyopharm Therapeutics, trimming expectations from a prior average in the low $20s to the high teens. Recent financing transactions extend the cash runway into 2026 and also dilute near term upside, despite a solid outlook for Xpovio sales and key myelofibrosis data in 2026.Narrativ-Update • Nov 27
KPTI: Extended Cash Runway Will Support Key Myelofibrosis Phase III Data
Analysts have lowered their price targets on Karyopharm Therapeutics, with reductions such as $19 from $30 and $6 from $8. They cite the impact of recent financing transactions while maintaining positive views on the company's risk profile and its cash runway extension, which is expected to support upcoming trial milestones.Narrativ-Update • Nov 11
KPTI: Upcoming Myelofibrosis Phase III Readout Will Drive Future Opportunity
Karyopharm Therapeutics’ analyst fair value price target has decreased by $1.00 to $14.67. Analysts cite recent financing transactions and updated growth forecasts as key factors behind the revision.Narrativ-Update • Oct 28
Extended Cash Runway Will Support Pivotal Phase III Clinical Milestones
Karyopharm Therapeutics' analyst price target has been reduced sharply from approximately $23.07 to $15.67 per share. Analysts cite the company’s recent strategic financing measures and updated projections following extended cash runway and upcoming clinical milestones.Narrativ-Update • Oct 13
Phase III Trials And Global Partnerships Will Advance Personalized Medicine
Karyopharm Therapeutics' analyst price target has been reduced from $8 to $6. This reflects analysts' views that, while strategic financing has extended the company's cash runway into Q2 2026, financial constraints and the timeline to key clinical trial readouts warrant a tempered outlook.Analyseartikel • Sep 11
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Held Back By Insufficient Growth Even After Shares Climb 65%
Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) shares have had a really impressive month, gaining 65% after a shaky...Narrativ-Update • Aug 15
Phase III Trials And Global Partnerships Will Advance Personalized Medicine
Karyopharm Therapeutics’ net profit margin has improved and its future P/E has declined—indicating stronger profitability and a more attractive valuation—while the consensus analyst price target remains unchanged at $25.92. What's in the News Provided 2025 earnings guidance, expecting total revenue between $140 million and $155 million, including U.S. XPOVIO net product and partner-derived revenue.Analyseartikel • Aug 14
US$25.92: That's What Analysts Think Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Is Worth After Its Latest Results
NasdaqGS:KPTI 1 Year Share Price vs Fair Value Explore Karyopharm Therapeutics's Fair Values from the Community and...Analyseartikel • May 24
Investors Don't See Light At End Of Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Tunnel And Push Stock Down 27%
Unfortunately for some shareholders, the Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) share price has dived 27% in the...Analyseartikel • May 22
Here's Why Shareholders May Want To Be Cautious With Increasing Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) CEO Pay Packet
Key Insights Karyopharm Therapeutics' Annual General Meeting to take place on 28th of May CEO Richard Paulson's total...
Neues Narrativ • Apr 08
Phase III SENTRY And XPOVIO Approvals Will Secure Future Success
Positive trial outcomes in myelofibrosis and endometrial cancer could significantly boost revenue and redefine care standards.Analyseartikel • Dec 24
Lacklustre Performance Is Driving Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) 27% Price Drop
Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) shareholders won't be pleased to see that the share price has had a very...Analyseartikel • Oct 01
Why Investors Shouldn't Be Surprised By Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Low P/S
You may think that with a price-to-sales (or "P/S") ratio of 0.7x Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) is...Analyseartikel • Aug 09
Karyopharm Therapeutics Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Shareholders might have noticed that Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) filed its second-quarter result this...Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2028 | 230 | -117 | N/A | N/A | 4 |
| 12/31/2027 | 155 | -135 | N/A | N/A | 6 |
| 12/31/2026 | 137 | -128 | N/A | N/A | 7 |
| 3/31/2026 | 151 | -195 | N/A | N/A | N/A |
| 12/31/2025 | 146 | -196 | -75 | -75 | N/A |
| 9/30/2025 | 143 | -125 | -89 | -89 | N/A |
| 6/30/2025 | 137 | -124 | -103 | -103 | N/A |
| 3/31/2025 | 142 | -63 | -123 | -123 | N/A |
| 12/31/2024 | 145 | -76 | -128 | -127 | N/A |
| 9/30/2024 | 148 | -87 | -120 | -120 | N/A |
| 6/30/2024 | 146 | -90 | -131 | -130 | N/A |
| 3/31/2024 | 140 | -141 | -118 | -118 | N/A |
| 12/31/2023 | 146 | -143 | -93 | -93 | N/A |
| 9/30/2023 | 146 | -140 | -101 | -101 | N/A |
| 6/30/2023 | 146 | -142 | -100 | -100 | N/A |
| 3/31/2023 | 148 | -158 | -109 | -109 | N/A |
| 12/31/2022 | 157 | -165 | -150 | -150 | N/A |
| 9/30/2022 | 250 | -88 | -97 | -97 | N/A |
| 6/30/2022 | 251 | -104 | -99 | -93 | N/A |
| 3/31/2022 | 234 | -108 | -119 | -113 | N/A |
| 12/31/2021 | 210 | -124 | -113 | -107 | N/A |
| 9/30/2021 | 119 | -206 | -169 | -163 | N/A |
| 6/30/2021 | 102 | -208 | -184 | -184 | N/A |
| 3/31/2021 | 113 | -201 | -168 | -168 | N/A |
| 12/31/2020 | 108 | -196 | -160 | -160 | N/A |
| 9/30/2020 | 91 | -201 | -169 | -169 | N/A |
| 6/30/2020 | 83 | -189 | -161 | -161 | N/A |
| 3/31/2020 | 59 | -186 | -169 | -169 | N/A |
| 12/31/2019 | 41 | -200 | N/A | -191 | N/A |
| 9/30/2019 | 23 | -209 | N/A | -200 | N/A |
| 6/30/2019 | 10 | -216 | N/A | -202 | N/A |
| 3/31/2019 | 20 | -206 | N/A | -191 | N/A |
| 12/31/2018 | 30 | -178 | N/A | -159 | N/A |
| 9/30/2018 | 32 | -159 | N/A | -116 | N/A |
| 6/30/2018 | 31 | -142 | N/A | -100 | N/A |
| 3/31/2018 | 12 | -138 | N/A | -84 | N/A |
| 12/31/2017 | 2 | -129 | N/A | -74 | N/A |
| 9/30/2017 | 0 | -117 | N/A | -88 | N/A |
| 6/30/2017 | 0 | -112 | N/A | -87 | N/A |
| 3/31/2017 | 0 | -112 | N/A | -86 | N/A |
| 12/31/2016 | 0 | -110 | N/A | -84 | N/A |
| 9/30/2016 | 0 | -112 | N/A | -85 | N/A |
| 6/30/2016 | 0 | -117 | N/A | -90 | N/A |
| 3/31/2016 | 0 | -119 | N/A | -97 | N/A |
| 12/31/2015 | 0 | -118 | N/A | -94 | N/A |
| 9/30/2015 | 0 | -115 | N/A | -86 | N/A |
| 6/30/2015 | 0 | -104 | N/A | -77 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: KPTI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Ertrag vs. Markt: KPTI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Hohe Wachstumserträge: KPTI wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.
Einnahmen vs. Markt: KPTIDie Einnahmen des Unternehmens (30.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (12.5% pro Jahr).
Hohe Wachstumseinnahmen: KPTIDie Einnahmen des Unternehmens (30.5% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von KPTI in 3 Jahren voraussichtlich hoch sein wird
Wachstumsunternehmen entdecken
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/11 18:30 |
| Aktienkurs zum Tagesende | 2026/06/11 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Karyopharm Therapeutics Inc. wird von 20 Analysten beobachtet. 7 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Colleen Kusy | Baird |
| Ying Huang | BofA Global Research |
| Harshita Polishetty | B. Riley Securities, Inc. |